After developing key methods to generate new antibodies, we continue to generate and refine human monoclonal antibodies both by adding novel functions allowing new therapeutic paradigms and developing high-throughput in vitro antibody generation to substitute animal experiments.
We partner with academia and pharma in the generation of new drugs against cancer, autoimmune diseases and infections using our world leading antibody phage display systems, including a comprehensive naïve functional human antibody gene libraries covering the world's antibody repertoire.
The control of biochemical milieu during the in vitro selection step can be employed to predetermine antibody properties at the very moment of selection, e.g. to avoid cross reactivity or generating compatible sandwich pairs. Engineering of antibodies for novel applications like intracellular protein knockdowns, or allosteric switches for affinity modulation, complement the animal-free antibody generation pipelines.
Our 30+ years with phage display is further employed to create creative new methods for antigen and biomarker discovery, e.g. ORFeome and Metaproteome display.
It is further used for in vitro evolution to fine tune various biochemical properties, like affinity, specificity or stability of proteins, or to adapt antibody properties to various applications, like biosensors or molecular machines.
Past or ongoing projects cover the following major topics, among others:
Animal-free generation of antibodies by phage display for research, diagnostics and therapy